Biovica International AB (Nasdaq First North Premier Growth Market:BIOVIC-B), a supplier of blood-based biomarker assays to monitor cancer progression, revealed on Thursday that it has been granted a new patent by the European Patent Office for its DiviTum TKa biomarker technology in the field of immuno-oncology.

The patent takes effect on 16 July 2025, upon its publication in the European Patent Bulletin.

Covering the use of Thymidine Kinase activity (TKa) as a marker to predict the efficacy of immune checkpoint inhibitors (ICIs) in cancer treatment, the new patent applies to patients initiating or currently receiving therapies targeting PD-1, PD-L1 or CTLA-4 proteins.

This innovation supports more accurate patient selection and aims to strengthen Biovica's position with pharmaceutical companies developing ICI therapies. The company anticipates improved potential for personalised treatment and monitoring of immunotherapy patients.

Biovica is pursuing equivalent patent protection in the United States, Japan and China to expand its global reach.